HC Wainwright Cuts Immunic (NASDAQ:IMUX) Price Target to $8.00

Immunic (NASDAQ:IMUX) had its price objective cut by HC Wainwright from $10.00 to $8.00 in a research note issued to investors on Friday,Benzinga reports. They currently have a buy rating on the stock.

Several other research firms have also recently commented on IMUX. Chardan Capital assumed coverage on Immunic in a report on Monday, September 29th. They issued a “buy” rating and a $13.00 price target for the company. D. Boral Capital lowered their price objective on Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday. Roth Capital initiated coverage on Immunic in a research note on Friday, November 7th. They issued a “buy” rating and a $3.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunic in a research note on Wednesday, October 8th. Finally, LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a report on Thursday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $7.40.

Immunic Price Performance

Shares of Immunic stock opened at $0.78 on Friday. The company has a market cap of $76.80 million, a PE ratio of -0.83 and a beta of 1.53. The firm has a fifty day moving average price of $0.83 and a two-hundred day moving average price of $0.86. Immunic has a fifty-two week low of $0.56 and a fifty-two week high of $1.42.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.05. Analysts expect that Immunic will post -0.94 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immunic

Institutional investors have recently added to or reduced their stakes in the company. Two Sigma Investments LP acquired a new position in Immunic in the third quarter valued at about $52,000. HB Wealth Management LLC bought a new position in shares of Immunic in the third quarter valued at approximately $81,000. Virtu Financial LLC acquired a new position in shares of Immunic in the 3rd quarter worth approximately $99,000. GSA Capital Partners LLP bought a new stake in Immunic during the 3rd quarter worth approximately $170,000. Finally, Jane Street Group LLC grew its position in Immunic by 279.3% during the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock worth $226,000 after acquiring an additional 152,726 shares during the last quarter. 51.82% of the stock is owned by institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.